mAbDx is pleased to announce it has been awarded an Oregon Venture Launch Grant to develop non-invasive (saliva-based) diagnostic tests for head and neck cancer. The award will support growth of mAbDx's pipeline of novel biomarkers and immunodiagnostics for cancer and inflammatory diseases.
Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer, with more than 48,000 new patients annually in the US and 500,000 worldwide. HNSCC is difficult to diagnose early, and has a poor prognosis when diagnosed late. Diagnostic tests that detect HNSCC early will improve patient outcomes and increase survival rates.
Oregon Venture Launch Grants are competitive translational research grants that support research with a strong potential to develop innovations that will benefit the public.